目的探讨研究低分子肝素在冠心病介入治疗中的临床疗效。方法收录2016年5月~2016年1 0月期间本院诊治的冠心病患者1 2 4例,以统计学随机表法分为普通肝素组(6 2例)和低分子肝素组(62例),分别开展普通肝素和低分子肝素介入治疗方案。比较两组冠心病患者的股动脉穿刺压迫止血平均用时,穿刺局部血肿发生率;并对比观察两组心血管不良事件的发生率。结果低分子肝素组患者的介入治疗效果良好,其股动脉穿刺压迫止血平均用时为(20.21±3.41)min、穿刺局部血肿发生率为4.84%(3/62)、非致死性心肌梗死发生率为4.84%(3/62)、心源性死亡0%(0/62)、脑卒中发生率为1.61%(1/62);普通肝素组统计结果分别为(27.57±5.31)min、17.74%(11/62)、19.35%(12/62)、0%(0/62)、4.84%(3/62)。对比于普通肝素组,除了心源性死亡发生率,两组对比结果无异(P>0.05);其余各项差异,低分子肝素组均明显更优,且统计学意义充分(P<0.05)。结论低分子肝素在冠心病介入治疗中的应用疗效,相较于普通肝素,更能够有效降低心血管不良事件的发生率及缩短穿刺出血压迫用时,降低穿刺局部血肿的发生风险,具有更高的临床安全应用价值。 Objective To investigate the clinical effect of low molecular weight heparin in interventional therapy of coronary heart disease. Methods One hundred and twenty-four patients with coronary heart disease diagnosed and treated in our hospital from May 2016 to January 2016 were divided into two groups: unfractionated heparin group (62 cases) and low molecular weight heparin group (62 cases) , Respectively, to carry out unfractionated heparin and low molecular weight heparin interventional treatment program. The incidence of local hematoma was compared between the two groups when mean femoral artery puncture hemostasis was used in patients with coronary heart disease. The incidence of cardiovascular adverse events was compared between the two groups. Results The interventional treatment in low molecular weight heparin group was effective. The average time of hemostasis in femoral artery puncture was (20.21 ± 3.41) min, the incidence of local hematoma in puncture was 4.84% (3/62), the incidence of nonfatal myocardial infarction was 4.84% (3/62), 0% (0/62) of cardiogenic death and 1.61% (1/62) of stroke respectively. The results of unfractionated heparin group were (27.57 ± 5.31) min and 17.74%, respectively 11/62), 19.35% (12/62), 0% (0/62), 4.84% (3/62). Compared with unfractionated heparin group, except for the incidence of cardiac death, the results of the two groups were no significant difference (P> 0.05); other differences, low molecular weight heparin group were significantly better and statistically significant (P <0.05) . Conclusion Low molecular weight heparin in the interventional treatment of coronary heart disease curative effect compared with unfractionated heparin, but also can effectively reduce the incidence of cardiovascular adverse events and shorten the puncture and bleeding oppression, reduce the risk of local hematoma puncture, with higher Clinical safety value.